Načítá se...
The BRAF(V600E) mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?
OBJECTIVES: Preclinical studies showed that BRAF(V600E) mutation significantly reduced radioiodine uptake and decreased the sensitivity to radioactive iodine (RAI) therapy. However, clinical data regarding its role in therapeutic decision making with respect to RAI therapy are currently insufficient...
Uloženo v:
| Vydáno v: | Nucl Med Commun |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282664/ https://ncbi.nlm.nih.gov/pubmed/30312216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MNM.0000000000000930 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|